Pathologic observations in human allograft recipients treated with FK 506 by Demetris, AJ et al.
. ~ 
Pathologic Observations In Human Allograft Recipients Treated With flb~ 
FK 506 ' 
A.J. Demetris, J.J. Fung, S. Todo. B. Banner. T. Zerbe. G. Sysyn, and T.E. Starzl 
FK 506, a powerful new immunosuppressant, has proved to be an effective drug for the prevention and 
treatment of allograft rejection in animals. I.. In some 
respects, it was even shown to be superior to CyA, which 
revolutionized solid organ transplantation a decade earlier. 
However, during trials in experimental animals, serious 
questions were raised regarding its potential toxicity. 
Wide-spread arterial necrosis, induction of a diabetic state, 
and renal tubular and liver damage were among the most 
worrisome harmful effects attnbuted to this agent.9-12 
These reported toxicities varied with the animal species 
used. Rats could be given relatively large doses with 
seemingly little consequence,I3 while dogs given the same 
amounts on a per weight basis experienced vomiting and 
emaciation, and often died.6 Evidence of a peculiar, non-
inflammatory necrosis of the media and periadventitia of 
muscular arteries was found at the time of death in the 
canine subjects.6.8·9-12 Nevertheless, our group6.1 and 
Ochiai et all~ noted the same lesions in animals who never 
received the drug, while some of the other reported side 
effects were not observed at all.6 •S• 13 These findings eased 
some, but not all, of the concern surrounding the use ofFK 
506 in humans. 
Encouraged by the promise of this agent and the incon-
clusive nature of the most serious potential side effects, 
clinical trials were cautiously undertaken in humans who 
had already received allografts. but whose organs were 
failing from rejection under conventional therapy, in which 
Cy A was the mainstay immunosuppressant. In fact, many 
ofthese first patients had already lost one or more grafts to 
rejection. The following report is an account of the patho-
logic findings in the organ allografts and other tissues from 
the patients who were the first to be given this drug. 
PATIENTS AND METHODS 
Patient Groups 
As mentioned previously, FK S06 was first aiven to patients in an 
attempt to prevent graft failure in those experiencing organ 
rejection despite optimal conventional Cy A and steroid therapy. 
Henceforth, these win be referred as "rescue" patients, and 
further classified by the type of organ allograft. All of these 
patients underwent allograft biopsy evaluation within I week 
before the initiation of FK S06 therapy. 
Reassured by the ability of FK S06 to halt the proeressioo of 
rejection in a number of the rescue patients and the relative lack 
of any apparent serious toxicities, patients who were experiencing 
unmanageable side effects from CyA or whose graft function had 
seriously deteriorated from unapparent causes were also switched 
to FK 506. These patients will also be referred to as "rescues," 
but were separated from those descnbed above. 
The last group of patients were those in whom FK 506 was used 
rrom the outset; these will be referred tou "primary" and further 
categorized as to the type of aIIograt\. All the primary patients 
underwent protocol biopsy evaluation at 7-10 days after transplan-
tation regardless of the clinical or serologic profile. Additional 
biopsies were obtained at the oaset of sraft dysfunction. A 
summary of the various treatment poops is shown in Table I. AD 
patients listed have had at least 1 month (up to 7 months) of 
clinical follow-up at the time of this writing. 
Analysis of Pathologic FlIldings 
For comparison analysis of the rescue patients before and after 
FK 506 therapy, the ronowing criteria were used. The severity of 
acute cellular rejection in the liver- specimens was graded accord-
ing to previously published criteria. 15 Since "chronic" rejection is 
difficult, if not impoSSible, to grade, specific histologic features 
were assessed and compared before and after the initiation of FK 
506 therapy. The specific histoJoeic: features analyzed included the 
severity of portal inftammation (mild, inflammation without ex-
pansion of the triad; moderate, expansion of the triad; and severe, 
marked expansion with spffiover- into the lobule and/or bridging). 
Duct damage was based on the percentage of affected ducts (mild, 
<25%; moderate 25-75%; and severe, >75%) and duct loss was 
based on the percentage of portal tnIcts without ducts but con-
taining arteries (mild. <40%; moderate, 4().75%; and severe, 
>75%) and the presence of centrilobular cholestasis, hepatocyte 
dropout, and hepatic venular sclerosis. Criteria for the grading of 
Table 1. Summary of the VIIrious FK 506 Treatment Groups 
Treatment Group Type d AIognII No. 01 Patien1s 
Rescue LNar 38 
Rescue' I<D1ey 5 
Rescue Cb;ter 2 
Rescue HeM 0 
Primary LNar 20 
Primaryt Kmey 3 
Primary QJSter 2 
Primary Heart 2 
, Two 01 these pallents were also IMIr aIogaIt recipients, and vBl)'ing degrees 
01 rejec:tIon were seen In boIh grafts. 
t Two 01 Ihese patients -., also kidney ""rescue. patients who had a new 
kidney grail placed al\er being switched ~ FK 508. 
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acute ceUular rejection of kidney and heart grafts were based on 
previously published criteria. I6.17 .. .. 
A group of 20 historic controls matched for age, disease, and 
United Network Organ Sharing priority statUti who were treated 
with Cy A and steroids were also analyzed for comparison with the 
primary FK S06 liver aUograft recipients. All graft pathology 
specimens taken from this group withio the first month after 
transplantation were subjected to the same scrutiny as the FK S06 
patients listed above. . . .' 
RESULTS 
Observations in Allografts 
liver Rescues (Rejection). Seventeen of the 24 patients 
switched from Cy A to FK S06 had liver biopsy findings 
which, in the author's experience, are harbingers of a 
progressive and largely irreversible fonn of rejection (fa-
ble 2), often called early "chronic" rejection or "vanishing 
bile duct syndrome." This rejection was characterized by 
a relatively mild mononuclear portal infiltrate, localized 
around and in the small bile ducts and associated with 
significant ductular epithelial cell damage. The duct cell 
damage took the form of paranuclear vacuolization and/or 
pyknosis, eosinophilic transformation of the cytoplasm, 
uneven spacing of the nuclei around the circumference of 
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the duct, and even focal duct loss. Clinically. these find-
ings correlated weD with the presence of marked eleva-
tions in the canalicular enzymes (alkaline phosphatase and 
gamma glutamyl transpeptidase). in the absence of any 
evidence of large duct obstruction. 
Eleven of the 17 patients showed histologic evidence of 
amelioration of at least one and often more of the his-
tologic parameterS'assessed after the switch from CyA to . 
FK S06 (fable 2). An example of a liver rescue in a patient 
with "chronic" rejection is shown in Fig I. Pathologically 
although the bile ducts had not completely returned to 
normal in follow-up biopsies in nine patients, marked 
decreases in liver'irijUiy tests were noted in six. Four 
others failed to resPond pathologicaDy on the most .recent 
biopsy and two lost their grafts to chronic rejection; both 
of these patients had already lost most of their bile ducts 
before being switched. There has been clinical improve-
ment in the remaining two patients who did not respond 
pathologically. No pathologic follow-up was available in 
three additional patients, although clinical improvement 
was noted. 
Six of the 24 patients in this group had biopsy findings 
which were best classified as acute cellular rejection, 
Table 2. Comparlaon of HIstologic FIndings In liver Allograft BIopsies Before and After TI'Mtment WIth FK 506 In UYer Rescuea 
WIth Rejection .. the 11me of the Switch From CyA to FK 506 
PTH'l< 508 Post.fK 508 
Pathology 01 PrevIous Failed Portal OudDam- POI1aI luct~ 
Patients GraII(l) InIIInvnaIion age Duct Loss Inflammation age 
R.F. GX1 ,GX2: CR and hepatitis Mild Mild None None None 
LW. GX1,3: arterial thrombus; Mild Moderate Minimal Minimal None 
GX2,4: CR 
Y.A.· GX1:CR Moderate MUd None Mild MId 
D.S·t None Severe Severe None None None 
M.B. None Moderate Severe Mild None Mild 
W.O. None Mild Mild None None None 
D.W. GX1:CR Moderate Severe Moderate Mild Moderate 
H.M. None Moderate Severe Moderate Mild Severe 
H.W.t None Severe Severe Minimal Mild Severe 
R.F.t None Moderate Moderate None NA NA 
F.B. GX1: ischemic injury Mild Moderate Mild Minimal Mild 
D.J. None Mild Severe Moderate Minimal Mild 
M.S. GX1: CR Moderate Moderate Mild NA NA 
C.C. None Moderate Severe Severe Mild Severe 
J.W. None Moderate Severe Mild Minimal Moderate 
P.H·t None Moderate Moderate None NA NA 
J.B.t None Minimal Mild Minimal None None 
L.S·t None Mild Mild None AU AU 
F.J. None Mild Severe Moderate Mild Moderate 
T.B. None Mild Moderate Minimal Minimal None 
R.U. None Mild Mild None Mild Mild 
L.K. None Mild Moderate Mild NA NA 
R.S. GX1: ischemic injury Mild Moderate None NA NA 
R.C. None Mild Moderate None Mild Moderate 
AbbnMatlons: GX, graft: CR. eIvonic rejection: NA. no! avaIabIe: AU. 1IUIopSy • 
• Patient was a liver and kidney allograft recipient and was swi1ched prWnarIy because of the rejecting kidney. 
t Patients willi acute cellular rejection. 
Ouct Loss 
None 
None 
None 
Mild 
Mild 
None 
Moderate 
Severe 
Severe 
NA 
Minimal 
Moderate 
NA 
Severe 
t.flllimal 
NA 
None 
AU 
Mild 
Mild 
None 
NA 
NA 
t.fJnimal 
PaIloIogIc 
foIow..up 
(d) Graft Status 
69 Functioning 
98 Failed: arterial 
thrombus 
93 Functioning 
51 Functioning 
65 Functioning 
32 Functioning 
30 Functioning 
36 Failed: CR 
27 Falled:CR 
Functioning 
9 Functioning 
9 Functioning 
Functioning 
11 Failed: CR 
8 Functioning 
Functioning 
17 Functioning 
Oied:sepsls 
39 Functioning 
32 Functioning 
30 Functioning 
Functioning 
Functioning 
12 Functioning: 
steatosis 
.. 
~ 
PATHOlOGIC OBSERVATIONS IN HUMAN ALLOGRAFT RECIPIENTS 
FIg 1. An example of a liver rescue with earty chronic rejection. 
(A) The pre-FK 506 biopsy showed a mild portal mononuclear 
Infiltrate with marked bile duct distortion (arrow), and clinically, the 
gamma glutgamyl transpeptidase was in the 2,000 range. (8) 
Sixty-fIVe days after the switch to FK 506, there was stiR a mild 
portal Infiltrate, but the duct damage was less severe (arrow). The 
gamma glutamyl transpeptidase serum activity had decreased to 
the 500-600 range. 
varying from histologically mild to severe, although clini-
cally, all were experiencing significant graft dysfunction. 
One of the most dramatic examples of a rescue from 
severe acute cellular rejection is illustrated in Fig 2. Four 
of these patients have had histologic follow-up, and all 
improved with the exception of one who lost his graft to 
chronic rejection 27 days after the switch to FK 506. 
One patient not included in Tables I and 2 was switched 
to FK 506, but was later withdrawn from therapy because 
of a mistaken diagnosis. The pre-FK 506 biopsy showed 
mild duct damage and little evidence of lobular disease 
activity other than marked centrilobular hepatocellular 
anisonucleosis. Since the patient's original disease was not 
hepatitis B, the diagnosis was not initially suspected, and 
B viral antigen stains were performed when the liver 
functions deteriorated after the switch to FK 506. Many 
cells were found to be infected with the B virus. 
• 
Other than the changes mentioned above, there were 
several other findings noted in some of the liver biopsy 
specimens after the switch to FK 506 which mayor may 
not be attributable to the drug. These included mild 
hydropic ceO swelling and thickening of the plates in zone 
I of the acinus and Kupffer cell hypertrophy. Only one of 
these patients developed cytomegalovirus (CMV) hepati-
tis. Another developed Kupffer cell granulomas, although 
no microorganisms or viral antigens could be detected by 
histochemical or immunohistochemical methods. 
liver Rescues (Renal Failure or Unexplained Groft 
DysfunctiOil'. There were 13 patients who were switched 
to FK 506 from Cy A for reasons other than pathologically 
severe acute or "chronic" rejection (Table 3), although 
four of them had a mild degree of acute cellular rejection 
on the pre-FK 506 biopsy. In five of the patients, the 
switch was made because of renal failure from CyA 
toxicity. One patient was switched because of steroid 
complications. Three other patients had lost prior grafts 
because of primary nonfunction, the causes of which were 
not apparent, and their second grafts were deteriorating 
due to unknown reasons. In the remaining patients, severe 
rejection was suspected clinically, but could not be verified 
histologically. 
None of the post-FK 506 biopsies from this group of 
patients demonstrated rejection; the others showed repair 
of previous injury, and two of the patients died (see 
Autopsy Studies, below). 
Kidney Rescues. There were five attempts to rescue 
rejecting kidney grafts. Four of the five had varying 
degrees of ongoing acute cellular rejection, chronic vascu-
lar changes, and interstitial fibrosis. One patient developed 
an acute humoral rejection after the switch to FK 506 and 
eventually lost the graft to this process. In total, four of the 
five rescue attempts were unsuccessful, and examination 
of the failed grafts revealed changes characteristic of 
"chronic" rejection, With marked obliterative arteriopa-
thy, interstitial fibrosis, and tubular atrophy. A monoclo-
nal (M, lambda) posttransplant Iymphoproliferative disor-
der was also discovered in the hilum of one of these 
rejected allografts. This particular patient had been given 
several steroid recycles and OKTI prior to the switch to 
FK S06 in an attempt to rescue his failing graft. Although 
no pathologic follow-up was available in the fifth patient, 
retransplantation was required and good results were 
obtained. 
Shortly (within 2 weeks) after the switch from eyA to 
FK 506, three of these patients developed glomerular 
capillary loop and polar arteriolar thrombosis. In retro-
spect, these may have been due to the Coadministration of 
Cy A with FK 506. Proximal tubular vacuolization was also 
seen, but had been there prior to the switch. 
"Cluster" Rescues. At the time of this writing, no 
pathologic fotlow-up was available in cluster allograft 
recipients who were switched to FK 506. 
Liver Primaries. The pathologic diagnoses of the timed 
protocol liver samplings or biopsies obtained at the time of 
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fig 2. All example of a liver rescue with severe acute ceHuiar rejection. (A) Severe acute celUar rejection 45 days posttransplanl Th/a 
biopsy was taken after a steroid recycle, (8) The patient was then treated with a 1o-day course of OKT3, and this biopsy was obtained 
at the completion of therapy. Although the portal Infiltrate (pt :: porta/ tract) has slightly decreased, there was centrilobular (arrow) dropout 
and portal-portal bridging and clinically, graft function deteriorated. (C) Fourteen days after the switch to FK 506, the portal infiltrate had 
largely subsided, but there was mild portal fibrosis (pt :: portal tract). Remnants of centrilobular damage were still apparent (arrow). (0) 
One month later, the liver architecture was returning toward normal, including the centrilobular region (arrow) and no aberrations of liver 
function tests were present (pt :: portal tract). 
graft dysfunction in the primary liver allograft recipients 
and the historic Cy A controls is shown in Table 4. Six of 
the 25 primary FK 506 liver allograft patients had findings 
in liver biopsy specimens that could be classified as acute 
cellular rejection and, in five of the six, the changes were 
mild. The sixth patient developed a more severe fonn of 
rejection which will be descn'bed in detail later. 
Six other primary FK 506 liver recipients had minor 
histologic alterations in their biopsies that were catego-
rized as "portal reactive change" (Fig 3). In these speci-
mens, there were one to two dozen inflammatory cells 
located in the interstitia of the portal triads, comprised 
mostly of mononuclear ~nsI a few of which appeared as 
blastic lymphocytes. These ~lls were intermixed with 
fewer eosinophils and neutrophils. No subendothelial lo-
calization was appreciated, and little or no evidence of bile 
duct damage was apparent. However, many of the con-
nective tissue interstitial cell nuclei appeared hyper-
trophic. These findings were most often seen in the proto-
col samples when there was little or no clinical evidence of 
liver dysfunction. The only apparent aberration was mild 
elevations of the gamma glutarnyl transpeptidase activity 
in the serum, which spontaneously resolved without addi-
tional immunosuppressive therapy. 
Two patients had mild portal eosinophilia and five others 
had either nonspecific changes or mild "preservation" 
injury unassociated with significant liver malfunction. A 
biopsy was inadvertently omitted in one patient. The 
biopsy results in the FK 506-treated liver primaries and 
CyA historic controls are shown in Table 4. 
Aside from the relatively mild nature of five of the six 
episodes of the "pathologic" acute cellular rejection, they 
appeared similar from a histologic perspective to those 
reported on conventional CyA therapy (Fig 4). Portal vein 
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Table 3. Pathology Finding. In liver Rescue Patient. In Whom CyA or Steroid ToxIcity Wu1he Reuon tor the SwItch or In Whom 
RejectIon W .. Suspected by the Clinicians 
Pathology 01 Previoua 
Grall Statui Pallen! F alad Grafts ,.,.FK 506 Biopsy DIagnosIs PosI-FK 506 BIopey ~ 
J.G. None Treated ACR, rePair'of harvesting Chronic choIestasIs Functioning 
Functloniilg J.B. GX1; PNF; ischemic Ischemic InjUry , Minimal choIestasis 
P.M.' None Mild ACR, sepsis NA cu~ 
J.C. GX1; PNF; ischemic M~ ACR, presecvation injury NA ~nctioning 
J.M. None Severe preservation Injury Repalr of preservation Injury Functioning 
A.T.' GX1 ; duct obstruction Ischemic Injury NA Functioning 
F.G. None Severe preservation Injury Repalr of preservation Injury Functioning 
C.K.' None Mild ACA, re8ctiYe c:hanges No!\Specffic changeI Functioi'ling 
T.R. None NonspecIfIc changes MIcrogranulomas . Functioni'Ig 
A.M .. None NA NA functioning 
J.s,' f'.Ione Sepsis, Ischemic irfJry Repair of ischemic injury functioning 
D.M" None NA Severe ischemic irPY Died 
G.S. GX 1; PNF; ischemic Mild ACR, preservation injury 
. i. • 
Cholangitis, sepsis Died: sepsis ARDS 
Abbreviatlona: PNF. pr\maIy nonfIMIctIon; GX. graft; ACR. ac:Ut, Qi!rUar rejection; NA, not available; ARDS. ~D~ cIstr_ ayncIIome .. 
, Patients switched 10 FK 506 because 01 renall8Ikn (CyA Ioxlclly) or st~ compIica1IonI. 
. , - '. " . 
phlebitis and bile duct damage were the hallmark features. 
The exceptions were the presence of marked'Kuptfer cell 
hypertrophy and portal eosinophilia. Also', phlebips of the 
portal and terminal hepatic' veins was more noticeable in 
the FK 506 patients with definite rejection. .. 
One patient developed a particularly severe form of 
rejection which deserves speciat attention because of its 
unique histologic characteristics (Fig 5) • . At day 6, this 
patient had findings typical and diagnostic of mild acute 
cellular rejection, although man~ eosinoph~s ,were noted. 
By 13 days, liver function had worsened. but a kinked 
biliary ~tent was found and bacteria were cultured from the 
liver tissue. A pathologic diagnosis of ongoing cellular 
rejection and cholangitis was rendered. Despite treatment 
with antibiotics and removal of the stent, liver functiOns 
continued to deteriorate and' a . repeat biopsy shoWed 
changes of severe acute cellular rejection with arterial 
subendothelial. inflammation. portal interstitial hemor-
mage, and centrilobular hepatocellular dropout. The 
unique finding was the presence of an arteritis and marked 
Table 4. Biopsy Pathology Dl&!9nosls In Specimens ObtaIned During Flm Month From Patients Treated From the outset WIth FK 506 
'. ' ... ' verSus li\Storlc Controls Treated With CyA . . 
patient 
A.D. 
CA 
D.B. 
I.C. 
J.C. 
D.F. 
G.G. 
T.H. 
N.H. 
S.K. 
S.M. 
S.M. 
A.M. 
D.M" 
S.R. 
D.R. 
J.S. 
H.S. 
~KpK 
KW. 
D~chRMU - " 
Mild focal ACR (1'1) 
Portal reactive change (14) 
poriaJ reactive change (12) -
Mild ACR (6); Moderate ACR, cholangitis (13); 
severe ACR E~TF -
Minimal portal eosinophin~ (8) 
Portal reactive change (11) 
Portal rea~ change (8) 
Mild ACR (3), mild oilgoing ACR (14) 
NSC (3,11) . . 
Mild portal eosinophUia (10) 
Portal reactive cNinge (8) 
Mild ACR (10) ., .. 
Mild ~C~ (11) 
Portal reactive change (14) 
NSC(11)" .::-. ;~ .. 
Mild preservation Injury (6, 10) 
NA DK~D , . 
Mild ACR (7) 
Mild steatosis (13) 
Mild pf8$8rvation injury (12) 
Patient 
T.F. 
G.K. 
L.K 
LK 
H.S. 
e2 
J.H. 
W.E. 
S.C. 
LC. 
LD. 
M.M. 
z.a 
H.I. 
C.K 
D.H. 
J.G. 
M.T. 
E.M. 
B.E. 
AbbrevIations: AeR, acute ceIIuIir ref«;tion; FG,faled ~alf; NA, not available; NSC, nonspecific changes . 
• Patient died." ' 
Moderate ACR (4, 13) 
FG, arterial Ihrornbosis (14) 
~ifd AcR (10) 
MildACR (9) 
Moderate preservation injury (4) 
Mild Pr8S8IVatlon Inpy (Sf 
M~ ACR (11) 
Modenite ACR (7) 
NA 
~ 
Mild ACR (30) 
NA 
Moderate ACR (9) 
ro, arterial thrombosis, mild-
D~teACoE4F 
NA 
MOderate ACR (11) 
r,md ACR, partially treated (9) 
Moderate ACR (10) 
Moderate ACR (20) 
Severe preseivation injury (12) 
~ 
'I 
t 
I. 
! 
! 
~ 
J 
f. 
i , 
J , 
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mas (n = 10) and sinusoidal cell hypertropby (Fig 6). No 
:::~:KKKfygagiKIacid-fast bacteria, CMV jiral antigens, or ~viral 
inclusions could be identified !n'tbC smail gran~omasK ., 
Fig 3. An example of portal reactive change. Although there is a 
mild portal infiltrate, no evidence of duct or venular endothelial 
damage Is seen, Clinically, this change was associated with mild 
elevations of the canaflCUlar enzymes that spontaneously resolved 
without additional therapy. 
eosinophilia, constituting greater than 50% of the intense 
inflammatory infiltrate, findings which were uncommonly 
encountered in rejection under CyA. 
Among the historic controls, 12 patients had histologi-
cally verified acute cellular rejection, whicb varied from 
mild (n = 6) to moderate (n = 6). A noticeable difference 
between the two groups was the severity of the portal 
infiltrate, which was less in the FK 506 patients when 
compared with the CyA-treated controls. Two patients in 
the control group lost grafts from bepatic arterial throm-
bosis, two had preservation injury, and no biopsies were 
available in four. 
Other liver biopsy findings in the primary FK 506 
patients included mild hepatocyte swelling and thkkening 
of the plates in zone I of tbe acinus, Kupffer cell granulo-
Fig 4. An example of mild acute cellular rejection In a primary 
liver recipient under FK 506 therapy. Focal bile duct damage and 
venous infiltration (arrows) are the characteristic features. 
Kidney Primtuies, There we~D three patients whose 
kidney grafts were placed uDder FK 506 theraPy. All three ' 
had' prior liver ~KD~ therefore bad been 00 CYA. Two 
of these patients 'wen:' also failed FK S06 kidney rescue 
attempts. One ofihese patients died wm severe pneumo-
nia 'and sepsis after hePatic retranspiantatiOI1 for B viral 
he~tisK At aUtopsy, no rejection was seen in the kidney 
graft. The secondP,8lit;ntlost'bec PrimarY FK S06 rel)al 
&nUt from a mycotic (Candida) aneurysm ,and thrombosis 
at the arterial anastomosis. The renal parenchyma'showed 
widespread polar arteriolar thrombosis, presumably from 
fungal seeding of the arterial blood. The last patient had a 
renal biopsy 42 days after placement of the new kidney; it 
showed moderate acute cellular rejection which responded 
to additional steroid therapy. 
Mitliliorgan Primary. There was one patient who re-
ceiyed separate liver, kidney, pancreas, and small intesti-
nal grafts under FK 506. Biopsies of the liver at 6, 1~I and 
30 days were unremarkable. However. the pancreas graft 
was removed at 30 days because of arterial thrombosis. 
The graft had mild iritersti!ial, fibrosis. accompanied' by a 
mild mononuclear infiltrate and areas offat necrosis. There 
was also evidence of fat necros~s in the abdominal fat, 
including that attached to the intestines. Several small 
arteries in the pancreas and intestines, near areas of fat 
necrosis, showed focal mural necrosis. 
Heart PrimtJries. 1.'wo patients have had pathologic 
follow-up after beart transplantation initiated under FK 
506. At I week, there was no evidence of lymphocytic 
inflammation. but by 2 weeks there was a mild perivascu-
lar lymphocytic infiltrate. some of which was blastic. No 
myocyte necrosis was seen, but eosinophils were noted 
within the perivascular space and scattered elsewhere in 
the interstitium. As in the liver primaries, rebiopsy I week 
later showed no evidence of inflammation. 
Autopsy Studies 
There were six deatbs in patients under FK 506 therapy, 
and five of the six autopsies were available for review at 
the time of this writing, except for neuropathology. The 
tr~tment groups, survival. duration of FK 506 therapy, 
and cause of death are listed in Table 5. Four of the six 
patients were liver rescues: one had acute cellular rejec-
tion, one lost a prior liver graft from primary nonfunction 
and his second graft was rapidly deteriorating, and a tbird 
had pancreatitis, wbich prompted the switch, in an attempt 
to lower the steroid therapy. The last rescue patient was 
the one withdrawn from FK 506 therapy because of 
mistaken diagnosis. 
Five of the six patients suffered from multiple intraop-
erative or postoperative complications, whicb made eval-
uation of autopsy findings difficult. Rather than describe in 
detail the findings in each case, the pathologic ch~es in 
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Fig 5. Severe rejection In a primary Over recipient under FK 506. (A) Six days after transplantation, a biopsy revealed changes 
characteristics of acute cellular rejection. (8) Two weeks later, the portal infiltrate had increased and bile duct damage was evident (arrow). 
(C) An inflammatory arteritis was also present in the same biopsy as shown in panel 8, as was (0) marked phlebitis of the tenninal hepatic 
venule. ,," " " " 
organ systems which are potential sites of FK 506 toxici-
ties are listed in Table 6. Most of the liver specimens 
showed centrilobular necrosis and/or congestion and hem-
orrhage, consistent with agonal hypotension."The kidneys 
showed varying degrees of tubular vacuolization, most 
noticeable in the proximal portions. Three of the patients 
had acute pancreatitis and focal necrosis Qf segments of 
the pancreatic arteries." There were multiple possiple eti-
ologies for the pancreatitis and in two patients, the pan-
creatitis was diagnosed clinically prior to the switch to FK 
506. Focal necrosis of the media. of small and medium-
sized muscular arteries was seen in the ~e three patients 
and was limited to the pancreatic and penp8.ncreatic intes~ 
tinal fat vascular beds, which also showed evidence of fat 
necrosis. One patient had arterial necrosis iri a vessel i~ the 
perirenal fat at the pelvic-ureter junction of the left kidney. 
The area was ~ggought" to have been traumatized while 
completing the lower ven3.I caval anastomosis during the 
difficult transplant operation, when 60 Uof blood were 
consumed. " " 
DISCUSSION 
The efficacy of FK S06 as an immunosuppressive agent 
was demonstrated in both the "rescues" and "primary" 
treatment groups. Since our experience with the extrahe-
patic organs is limited, the following comments are largely 
restricted to liver allOgraft "recipients. The ability of FK 506 
" " 
to slow or stop, and possibly reverse, the progression of 
the alterations associated" with the early phases of "chron-
ic" rejection in over 50% of the patients with this diagnosis 
\.V8s the most surprising finding. Although a longer period 
of follow-up is needed to confirm this observation, in our 
experience, any res~ in patients with elevated cana-
licular enzymes aDd Severe bile duct damage on biopsy is 
unusual. Most of thoSe who di4 not respond had already" 
lost more than 50% of their bile ducts and had obliterative 
arteriopathy confirmed by. exammation of the allograft 
hepatectomy specimens. "" 
FK 506 was alSo effective in the treatment of acute 
cellular" rejection, t~a used in a manner similar to ste-
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FIg 8. Other findings In liver biopsies from patients treated with 
FK 506 Included (A) smaH Kupfer cell granulomas and mlcroab-
scesses (arrows), although no microorganisms could be detected, 
(8) mild hydropic swelling of periportal hepatocytes (arrows), and 
(C) sinusoidal cell hypertrophy. 
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roids or OKT3, bUl-waS seemingly:more potent. The 
reversal illustrat~gn"1D~1fO wB:itheD:~clraraatic ex~­
pleI:~ ~rrref~~~~~ t~Ef~ItfeeDilK~~I~~ a 
steroid recycle forow~ by nhqPK~D~r"Ifm:D~·D"II~~~::~-: . 
Base.d on' mrnt~Fiopsf ev8iU8tioa. FK ~MS was 
equaIlyefl'ectivi "·· .. ~tive therapy in the primary live.-
• nb in'" ruladCncf/oficute Cellular ·Cction :r 30% dUriDa &ri\"'PoS.raiive month. ~s Per-
centa&e is approxinwetyh~ thai seen in the historic 
CyA-~ted cOntrols (60%). A' simi1ar figUre for CyA-
treated patiCnts Ifi~ been reported at several institu~ 
tions~ 18.19 FurthennOie; au but one of the episodes re-
spoOded promp~y ~oa steroid bolus, and' no OKT3 was 
reQuired in any patient. . . :,' :' • ' 
The tllstologic appearance of acute ceDuJar rejection of 
the liver under FK 506 therapy was siDular to that seen in 
the Cy A-ti-eated patients. The characteristic' features were 
a predominantly mononuclear port8I tract Infiltrate, com~ 
bined with evidence of bOe duct and venous endothelial 
infiltra~ion and damage. However, eosinophils were quite 
prominent in several cases, rriarked' sinusoidal Cell hyper-
trophy was often a conspicuous find!ng, ~d the venous 
inIDiration, when present, was', more apparent. 'Although 
th~ histolo~ changes attributed to acute cellular rejection 
in .these patients may raise the consideration 'of a drua 
reaction, the triad 'of mononuclear portal infiltrate associ-
ated with bUe duct and venOus endothelial damage, com-
bined with timing of reaction and response to steroid ' 
therapy, is more characteristic of rejection. Eosinophils 
may be seen in both a rejection and a drug reaction but, in 
a liver transplant patient. the former is a much more 
common cause of tissue and peripheral eosinophilia. zo 
Based on the information to date, it was diflicult to 
attn'bute any specific morphologic 'finding to FK 506 tox-
icity. Minor alterations that were seen in association with 
the agent were mild periportal hepatocellular swelling. 
Kup6'er cell hypertrophy, and mild tubular vacuolization 
of the kidneys. The small Kup6'er granulomas present in 
the primary patients were not as conspicuous in the rescue 
group. Although some of these morphologic alterations 
have been associated with hepatic toxicity of other 
macrolides21 (FK 506 is a macrolide), others have not, and 
cholestasis was generally not prominent, as reported in 
nongrafted livers with erythromycin-associated liver in-
jury. Nevertheless, neither organ was the site of any 
mOrphologic or functional alteration, which might cause 
the use of FK 506 in humans to be questioned. 
The vascular necrosis and induction of a diabetic state in 
animals were the most worrisome changes that have been 
ascribed to' FK 506 toxicity.1-12 The vascular lesion ob-
served in dogs was best described as focal medial necrosis 
and not true vasculitis, since an inftammatory component 
Was rarely encountered. However, the nature of the lesion 
.is puzzling becaus!= an indistinguishable lesion was found 
in control animals, by us6.1 and by Ochiai et aI,l" with 
equa. frequency and severity. Although the morphologic 
changes are far from specific, arterial necro!!is can bC seen 
. ~ . 
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Table S. Treatment Groups, SUrvival, Duration of Therapy, and Cause of Death In Patients Who DIed While on FK 506 Therapy 
Duration 01 FK 506 
Pa1IenI Treatment Group SuIvival(d) Therapy (d) CauIe 01 0eaI1 
D."'. liver primary 14 14 Cardiac arrest 
M.S.' liver primary 10 10 Cerebellar hernoohage 
A.N.t liver rescue 152 5 Necrotizing pneumonia 
G.S. liver rescue 28 13 SepsIs, AROS, pancreatitis 
LS. liver rescue 17 6 SepsIs. AROS, OIC 
O.M. liver rescue 30 20 SepsIs 
Abbreviallons: AAOS. IWII resplraloty dI*_ ayndtome; OIC. disseminated Intravascular COI9Jlalion. 
• Pallenl not IncA.Ided In primaIy 1st repoI1IId In Table 4. 
t PatIenI rernDI\Ied from FK 506 after Iver ..... from UmInant hepatitis B. 
in rodents with the administration of dopaminergic 
agents,22 which were received by most of the patients who 
died while on FK 506. 
In humans under FK 506 therapy, arterial necrosis was 
seen in four patients; the arterial necrosis was limited to 
the pancreatic and peri pancreatic intestinal tissue in three 
patients with acute pancreatitis. Although arterial necrosis 
as a consequence of pancreatitis in humans had been 
reported by Rich and Duff in 1938,21 mention of this lesion 
has an but disappeared from the modern pathology litera-
ture. The only evidence of arterial damage outside this 
area was encountered in the perinephric fat near the 
pelvic-ureter junction of the left kidney, which serves as 
the operative bed for the lower venal caval anastomosis. 
To date, 00 arterial necrosis has been detected in the heart, 
kidney. liver, spleen, or other extraabdominal organ. 
The pancreas has also been cited as a possible target for 
serious FK 506 toxicityK9-f~ Of the six patients who died, 
four had acute pancreatitis at autopsy; although in two the 
pancreatitis was present before the switch to FK 506. In 
those without pancreatitis, the islets were intact and no 
consisteDt morphologic alteration was noted. Further-
more. no specific pancreatic endocrine or exocrine func-
tional defect has been noted in the patients maintained on 
this agent (D.H. Van Thiel, personal communication). 
FmaUy, one is faced with the task ofrendering an overall 
interpretation of the findings reported above. It seems 
fairly clear that FK 506 is a potent immunosuppressive 
agent capable of effectively treating established acute (and 
even the early phases of) chronic rejection. FK S06 is 
somewhat unique in that it can be used as preventive or 
primary therapy as well as a "rescue" agent and appears 
to be superior to all antirejection drugs in the present 
arsenal. To date, any potential acute toxicities have not 
been blatant or consistent enough to recognize a pattern of 
association with the drug. Although vascular necrosis was 
seen in several patients at autopsy, it was generally limited 
to the pancreatic and peripaocreatic intestinal tissues, and 
associated with acute pancreatitis or vascular trauma. 
Using Irey's criteria24 for analyzing possible adverse drug 
reactions, from a conservative perspective, we can say at 
this point that an association between these two compli. 
cations is possible, but not likely. The encouraging results 
to date endorse continued clinical trials, from which more 
Table 6. HistologiC FInding. In Organa That are Potential Sites of FK 506 Toxicity In Patients Who Died While on Thentpy 
Palient l'-' Klct1ey Panc:reM 
D.M. Microabscesses; no Mild arterial and arteri- None 
rejection oIonephrosclerosis: 
Fabray's heterozygote 
M.S. Focal infarcts and con- MarI<ed tubular vacuoliza- None 
gestion; minimal lion: congestion 
rejection 
A.N." Centrlfobufar congestion Mild lubular vacuolization: Acute pancreatitis with 
and hemorrhage no rejection acinar dilatation and 
focal arterial necrosis 
G.S. Congestion and focal M'lllimaIlubular vacuoliza- Autolysis with tocaI pan-
mild rejection lion; changes of A TN creatitis; mild intersti-
lial fibrosis 
L.S. Congestion: mild focal Focal Infarct: marked to- Acute hemorrhagic pan-
rejection blUr vacuolization; 00' creatitis with arterial 
casionaI polar arteriolar necrosis and Ihrombo-
IhrombosIs sis 
Abbreviations: A TN. 80JIe tubular necrosis; lAD. left anterior descending coronary arteIy • 
• Palienl was taken 01 FK 506 belate dealll because 01 mistaken dagnosis 01 hepatitis B. 
Blood Vessels Other 
Atherosclerosis of LAD: Severe coronary artery 
hypertensive pulmo- atherosclerosis 
nary arteriopalhy 
Focal mural necrosis of Cerebellar hemorrhage 
arteries in perinephric 
fat of left renal peMs 
Focal thrombosis and Severe necrotizing 
necrosis of pancreatic pneumonia (poIymi-
arteries crobial) 
Infarcted colonic epiploic Subhepatic abscess; 
with necrotic artery organizing diffuse 
alveolar damage 01 
lungs 
Intraluminal fibrin large pulmonary 
thrombi in pulmonary Ihromboembolus 
arteries, submucosal 
veins of colon and 
renal polar ar1eriofes 
.,',. 
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information on the effectiveness and long-term safety of, ' 
FK 506 can be obtained. 
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